Press Release

Lung Cancer Diagnostics Market to Grow with a CAGR of 6.86% through 2029

Rise of liquid biopsies are expected to drive the Global Lung Cancer Diagnostics Market growth in the forecast period, 2025-2029

According to TechSci Research report, “Lung Cancer Diagnostics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, the Global Lung Cancer Diagnostics Market stood at USD 1.41 billion in 2023 and is anticipated to grow with a CAGR of 6.86% in the forecast period, 2025-2029. Lung cancer remains a pressing global health concern, with its high mortality rate and the need for early detection and advanced diagnostic solutions. The foremost driver of the Global Lung Cancer Diagnostics Market is the persistently high incidence of lung cancer worldwide. This deadly disease is primarily associated with factors like smoking, exposure to environmental pollutants, and genetic predisposition. The increasing prevalence of these risk factors has led to a growing number of lung cancer cases, necessitating effective diagnostic tools and early detection methods.

Early detection is crucial for improving the prognosis and overall survival rates of lung cancer patients. As a result, there is a growing emphasis on the importance of early diagnosis, which has spurred the development and adoption of various diagnostic modalities. Patients diagnosed at an earlier stage have a wider range of treatment options, and the success of therapies is often significantly higher.

Diagnostic imaging technologies, such as X-rays, computed tomography (CT) scans, and positron emission tomography (PET) scans, have made remarkable progress in recent years. These technologies are vital for the visualization of lung tumors and the staging of cancer. Advancements in imaging have enhanced the accuracy and efficiency of lung cancer diagnostics, enabling healthcare professionals to make more informed decisions regarding treatment.

Molecular diagnostic techniques have revolutionized the field of lung cancer diagnostics. Polymerase chain reaction (PCR), next-generation sequencing (NGS), and other advanced molecular tests allow for the identification of specific genetic mutations and alterations in lung cancer cells. This information is critical for developing targeted therapies and personalized treatment plans, which can lead to better outcomes and fewer side effects for patients.

Liquid biopsies represent a groundbreaking advancement in lung cancer diagnostics. These non-invasive tests involve the analysis of circulating tumor DNA (ctDNA) and other biomarkers in a patient's blood or other bodily fluids. Liquid biopsies are not only less invasive but also offer the advantage of detecting cancer-related mutations and changes in real-time, making them invaluable for monitoring disease progression and treatment efficacy. 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Lung Cancer Diagnostics Market


The Global Lung Cancer Diagnostics Market is segmented into type, test, regional distribution, and company

Based on the type, non-small cell lung cancer (NSCLC) emerged as the dominant segment in the global lung cancer diagnostics market in 2023. NSCLC encompasses several subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each with unique characteristics and genetic profiles. These subtypes require distinct diagnostic approaches to determine the most appropriate treatment strategy. The diversity within NSCLC drives demand for specialized diagnostic techniques, such as molecular diagnostics, to accurately identify specific genetic mutations, guiding precision medicine interventions. Given its prevalence and diversity, NSCLC has been a major focus of research efforts. Clinical trials, new diagnostic technologies, and innovative treatment approaches are often centered around NSCLC, making it a key driver of market demand. The high level of investment and research in NSCLC diagnostics and treatment translates into an expanded range of diagnostic services and tools for this type of lung cancer. Recent advancements in the treatment of NSCLC have been closely linked to diagnostic breakthroughs. The development of targeted therapies and immunotherapies, which are highly effective in certain NSCLC subtypes, underscores the importance of precise diagnostics to identify patients who will benefit the most. The evolving landscape of NSCLC therapies further emphasizes the need for advanced diagnostic methods to select the most suitable treatment options.

Based on the test, the imaging test segment emerged as the dominant player in the global lung cancer diagnostics market in 2023. CT scans play a pivotal role in staging lung cancer, helping healthcare professionals determine the extent of the disease's spread. Accurate staging is essential for treatment planning and prognosis assessment. Furthermore, CT scans are instrumental in monitoring the progression of lung cancer and assessing the response to treatment over time, making them indispensable for the ongoing management of the disease. Early diagnosis is crucial for improving patient outcomes, as it enables healthcare providers to catch the disease at a more treatable stage. The ability of CT scans to visualize lung tumors and lesions, even before symptoms manifest, makes them an essential tool for early detection. Imaging tests, particularly CT scans, are non-invasive and relatively comfortable for patients. They do not require surgical procedures or the collection of tissue samples, which can be intimidating and invasive. This non-invasive characteristic promotes higher patient compliance and encourages more individuals to undergo regular screenings.

North America emerged as the dominant player in the global lung cancer diagnostics market in 2023, holding the largest market share. North America has made significant strides in promoting the importance of early detection of lung cancer. Public awareness campaigns, healthcare initiatives, and widespread access to lung cancer screening programs, including low-dose computed tomography (LDCT) scans, have encouraged individuals to undergo regular screenings. This emphasis on early detection has driven the demand for lung cancer diagnostic services. North America is a hub for medical research and innovation. The region hosts numerous research institutions, pharmaceutical companies, and diagnostic technology developers at the forefront of advancements in lung cancer diagnostics. Ongoing research and the development of cutting-edge diagnostic tools contribute to the region's leadership in the market.


Major companies operating in Global Lung Cancer Diagnostics Market are:

  • Sanofi S.A.
  • Roche Diagnostics
  • bioMérieux SA
  • Qiagen N.V.
  • Agilent Technologies
  • Thermo Fisher Scientific Inc.
  • AstraZeneca plc
  • Illumina Inc.
  • Janssen Pharmaceuticals, Inc
  • Abbott Laboratories Inc.


Download Free Sample Report

Customers can also request for 10% free customization on this report


“The Global Lung Cancer Diagnostics Market is poised for significant growth in the coming years. With increasing awareness campaigns and a growing emphasis on early diagnosis, more individuals are likely to seek lung cancer screenings. Advancements in diagnostic technologies, such as liquid biopsies, molecular tests, and artificial intelligence, will continue to improve the accuracy and efficiency of lung cancer detection. Moreover, the prevalence of lung cancer, particularly in regions with high smoking rates, will sustain demand for diagnostic services. As precision medicine gains momentum, the integration of molecular diagnostics and targeted therapies will further enhance patient outcomes. Public and private investments, coupled with robust research efforts, will play a pivotal role in driving innovation in this market.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Lung Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By Type (Small Cell Lung Cancer, Non-small Cell Lung Cancer), By Test (Imaging Test, Biopsy, Sputum Cytology, Molecular Test, Others) Region and Competition”, has evaluated the future growth potential of Global Lung Cancer Diagnostics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Lung Cancer Diagnostics Market.



Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]


Relevant News